Harvest CSI Hong Kong Connect Innovative Drug Index ETF Units

An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.

520970 trades at 1.062 CNY today, its price has risen 2.81% in the past 24 hours. Track more dynamics on 520970 price chart.

520970 net asset value is 1.06 today — it's risen 4.80% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.

520970 assets under management is ‪1.05 B‬ CNY. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.

Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.

520970 expense ratio is 0.60%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.

No, 520970 doesn't pay dividends to its holders.

520970 trades at a premium (0.27%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.

520970 shares are issued by Harvest Fund Management Co., Ltd.

520970 follows the CSI Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

The fund started trading on Jul 30, 2025.